Genmab, Medarex and Glaucus Announce Collaboration to Develop Human Antibody Therapeutics and Proteomics Technology

'Highest Quality Antibodies' for the Human Proteome Project



Apr 02, 2001, 01:00 ET from Genmab A/S

    MCLEAN, Va., April 2 /PRNewswire/ --
 Genmab A/S (CSE: GEN and Neuer Markt: GE9D), Medarex (Nasdaq: MEDX), and
 Glaucus Proteomics B.V., a privately held company incorporated in The
 Netherlands, announced today that they have entered into a collaboration to
 develop new antibody therapeutic products to novel disease targets discovered
 by Glaucus.  Using Medarex's HuMAb-Mouse(R) technology, Glaucus intends over
 the forthcoming years to establish a warehouse of fully human antibodies that
 will be used to construct an antibody reporter matrix.  Glaucus expects to use
 the matrix for signature profiling of human tissues in health and disease via
 chip-based differential analysis of protein expression levels, i.e. in a
 manner similar to a cDNA biochip, but directed at the molecular workhorses of
 biology -- proteins.
     Apart from screening applications, some of these human antibodies are
 expected to be employed for diagnostics and therapeutic applications.  In
 exchange for the rights to use fully human antibodies in connection with its
 proteomics technology, Glaucus will provide all the novel targets it discovers
 through its own research efforts using the HuMAb technology to the
 collaboration.  The alliance is intended to help ensure rapid progress from
 target discovery to the development of therapeutic agents.  Further details
 relating to experimental procedures and current deliverables in this sector
 will be reported today by Glaucus at the first Human Proteome Project meeting
 in McLean, Virginia.
     "Our high affinity human antibodies married to proteomics technology are
 an ideal partnership," said Lisa. N. Drakeman, Ph.D., Chief Executive Officer
 of Genmab.  "We believe that this collaboration has the potential to discover
 vital information about many disease states and to provide many novel disease
 targets that could lead to numerous new antibody products.  This fits in with
 Genmab's business plan to develop a broad portfolio of new antibody
 therapies."
     "We believe that proteomics and human antibodies will lead to many
 opportunities for new disease treatments, and we are extremely pleased to be
 working together with Glaucus and Genmab to achieve that goal," said Donald L.
 Drakeman, President and Chief Executive Officer of Medarex.
     "With Medarex and Genmab, we intend to transform a powerful enabling
 technology in proteomics that is centered on target discovery into one which
 is also linked to a drug warehouse of pre-screened fully human antibodies.  We
 are delighted to work together with such prestigious partners in the field of
 monoclonal antibodies", said the COO of Glaucus, Prof. Ian Humphery-Smith,
 speaking from the Human Proteome Project Meeting in McLean, Virginia.  "For
 us, it is of paramount importance to access the highest quality antibodies
 from the outset of a program designed to raise antibodies against the
 constituents of the human proteome.  Indeed, it would appear highly counter
 productive for us to identify targets on such a large scale using antibodies,
 if we then had to raise another set of human antibodies to the very same
 targets for therapeutic applications.  Thus, not only does this present a
 cost-effective route going forward, we believe it opens up several highly
 attractive business models to the signatories of this alliance both in the
 short and longer term."
     "It is unlikely that the Human Proteome Project will be completed without
 the systematic development of high affinity and high specificity antibodies
 directed against the output of each and every Open Reading Frame in the Human
 Genome.  The advantage of traditional hybridoma technologies for the
 production of monoclonal antibodies is the high ligand-binding affinities
 produced, which ultimately may translate into potentially useful assay
 sensitivity," said Prof. Humphery-Smith.
     Immunization and antibody screening procedures will be conducted in
 parallel and based on Glaucus technologies for rendering antibody production
 genomically relevant. In addition, it is expected that Medarex, Genmab and
 Glaucus will identify further areas for synergistic activities and mutual
 benefit during the course of this agreement.
     In order to evaluate both ligand recognition and potential target
 cross-reactivity, antibodies will have been screened against large numbers of
 recombinant antigens laid down on glass slides using Glaucus proprietary
 surface chemistries and employing proprietary extreme-HTS robotic engines
 capable of screening more than 100,000,000 ELISA-equivalents per day per
 robot.  The latter robots have recently completed two years of prototyping and
 are awaiting shipping to Glaucus facilities in The Netherlands.  For more
 information about Glaucus, visit www.GlaucusProt.com .
 
     Genmab A/S is a biotechnology company that creates and develops fully
 human antibodies for the treatment of life-threatening and debilitating
 diseases.  Genmab has four products in development to treat cancer, rheumatoid
 arthritis and other inflammatory conditions, and intends to assemble a broad
 portfolio of new therapeutic products arising from research into the human
 genome.  At present, Genmab's commercial opportunities are based upon research
 conducted at leading international companies, such as Immunex Corporation,
 Gemini Genomics plc, Oxford GlycoSciences Ltd., Eos Biotechnology Inc. and
 Medarex, Inc. as well as in its own laboratories.  A broad alliance provides
 Genmab with access to Medarex's array of proprietary technologies, including
 the UltiMAb(TM) platform for the rapid creation and development of fully human
 antibodies to virtually any disease target. For more information about Genmab,
 visit www.genmab.com
 
     Medarex is a biopharmaceutical company developing monoclonal
 antibody-based therapeutics to fight cancer and other life-threatening and
 debilitating diseases.  Medarex has assembled a broad platform of patented
 technologies for antibody discovery and development, including the UltiMAb(TM)
 Human Antibody Development System(SM) for the creation of high-affinity, fully
 human antibodies; T-12 Development(SM) offering the potential to move from
 target to trial in approximately 12 months; and Trans-Phage Technology(SM)
 combining high throughput screening with fully human antibody development.
 Medarex creates and develops fully human antibodies for itself and others,
 offering a full range of antibody development capabilities, including
 pre-clinical and clinical manufacturing services.  For more information about
 Medarex, visit its Web site at http://www.medarex.com .
 
     Except for the historical information presented herein, matters discussed
 in this press release are forward-looking statements that are subject to
 certain risks and uncertainties that could cause actual results to differ
 materially from any future results, performance or achievements expressed or
 implied by such statements.  Statements that are not historical facts,
 including statements preceded by, followed by, or that include the words
 "believes"; "anticipates"; "plans"; "expects"; "estimates"; or similar
 statements are forward-looking statements.
 
     For Medarex:  Risks and uncertainties include risks associated with
 product discovery and development as well as risks detailed from time to time
 in Medarex's public disclosure filings with the U.S. Securities and Exchange
 Commission (SEC), including its Annual Report on Form 10-K for the fiscal year
 ended December 31, 1999, subsequent Form 10-Q and Form 8-K filings or in
 Genmab's filings with the Copenhagen Stock Exchange and the Neuer Markt.
 Copies of Medarex's public disclosure filings are available from its investor
 relations department.  There can be no assurance that such development efforts
 will succeed, that such products will receive required regulatory clearance or
 that, even if such regulatory clearance were received, such products would
 ultimately achieve commercial success.
 
     HuMAb-Mouse(R) is a registered trademark of Medarex, Inc.  UltiMAb(TM) is
 a trademark of Medarex, Inc.  Human Antibody Development System(SM), T-12
 Development(SM) and Trans-Phage Technology(SM) are service marks of Medarex,
 Inc.
 
 

SOURCE Genmab A/S
    MCLEAN, Va., April 2 /PRNewswire/ --
 Genmab A/S (CSE: GEN and Neuer Markt: GE9D), Medarex (Nasdaq: MEDX), and
 Glaucus Proteomics B.V., a privately held company incorporated in The
 Netherlands, announced today that they have entered into a collaboration to
 develop new antibody therapeutic products to novel disease targets discovered
 by Glaucus.  Using Medarex's HuMAb-Mouse(R) technology, Glaucus intends over
 the forthcoming years to establish a warehouse of fully human antibodies that
 will be used to construct an antibody reporter matrix.  Glaucus expects to use
 the matrix for signature profiling of human tissues in health and disease via
 chip-based differential analysis of protein expression levels, i.e. in a
 manner similar to a cDNA biochip, but directed at the molecular workhorses of
 biology -- proteins.
     Apart from screening applications, some of these human antibodies are
 expected to be employed for diagnostics and therapeutic applications.  In
 exchange for the rights to use fully human antibodies in connection with its
 proteomics technology, Glaucus will provide all the novel targets it discovers
 through its own research efforts using the HuMAb technology to the
 collaboration.  The alliance is intended to help ensure rapid progress from
 target discovery to the development of therapeutic agents.  Further details
 relating to experimental procedures and current deliverables in this sector
 will be reported today by Glaucus at the first Human Proteome Project meeting
 in McLean, Virginia.
     "Our high affinity human antibodies married to proteomics technology are
 an ideal partnership," said Lisa. N. Drakeman, Ph.D., Chief Executive Officer
 of Genmab.  "We believe that this collaboration has the potential to discover
 vital information about many disease states and to provide many novel disease
 targets that could lead to numerous new antibody products.  This fits in with
 Genmab's business plan to develop a broad portfolio of new antibody
 therapies."
     "We believe that proteomics and human antibodies will lead to many
 opportunities for new disease treatments, and we are extremely pleased to be
 working together with Glaucus and Genmab to achieve that goal," said Donald L.
 Drakeman, President and Chief Executive Officer of Medarex.
     "With Medarex and Genmab, we intend to transform a powerful enabling
 technology in proteomics that is centered on target discovery into one which
 is also linked to a drug warehouse of pre-screened fully human antibodies.  We
 are delighted to work together with such prestigious partners in the field of
 monoclonal antibodies", said the COO of Glaucus, Prof. Ian Humphery-Smith,
 speaking from the Human Proteome Project Meeting in McLean, Virginia.  "For
 us, it is of paramount importance to access the highest quality antibodies
 from the outset of a program designed to raise antibodies against the
 constituents of the human proteome.  Indeed, it would appear highly counter
 productive for us to identify targets on such a large scale using antibodies,
 if we then had to raise another set of human antibodies to the very same
 targets for therapeutic applications.  Thus, not only does this present a
 cost-effective route going forward, we believe it opens up several highly
 attractive business models to the signatories of this alliance both in the
 short and longer term."
     "It is unlikely that the Human Proteome Project will be completed without
 the systematic development of high affinity and high specificity antibodies
 directed against the output of each and every Open Reading Frame in the Human
 Genome.  The advantage of traditional hybridoma technologies for the
 production of monoclonal antibodies is the high ligand-binding affinities
 produced, which ultimately may translate into potentially useful assay
 sensitivity," said Prof. Humphery-Smith.
     Immunization and antibody screening procedures will be conducted in
 parallel and based on Glaucus technologies for rendering antibody production
 genomically relevant. In addition, it is expected that Medarex, Genmab and
 Glaucus will identify further areas for synergistic activities and mutual
 benefit during the course of this agreement.
     In order to evaluate both ligand recognition and potential target
 cross-reactivity, antibodies will have been screened against large numbers of
 recombinant antigens laid down on glass slides using Glaucus proprietary
 surface chemistries and employing proprietary extreme-HTS robotic engines
 capable of screening more than 100,000,000 ELISA-equivalents per day per
 robot.  The latter robots have recently completed two years of prototyping and
 are awaiting shipping to Glaucus facilities in The Netherlands.  For more
 information about Glaucus, visit www.GlaucusProt.com .
 
     Genmab A/S is a biotechnology company that creates and develops fully
 human antibodies for the treatment of life-threatening and debilitating
 diseases.  Genmab has four products in development to treat cancer, rheumatoid
 arthritis and other inflammatory conditions, and intends to assemble a broad
 portfolio of new therapeutic products arising from research into the human
 genome.  At present, Genmab's commercial opportunities are based upon research
 conducted at leading international companies, such as Immunex Corporation,
 Gemini Genomics plc, Oxford GlycoSciences Ltd., Eos Biotechnology Inc. and
 Medarex, Inc. as well as in its own laboratories.  A broad alliance provides
 Genmab with access to Medarex's array of proprietary technologies, including
 the UltiMAb(TM) platform for the rapid creation and development of fully human
 antibodies to virtually any disease target. For more information about Genmab,
 visit www.genmab.com
 
     Medarex is a biopharmaceutical company developing monoclonal
 antibody-based therapeutics to fight cancer and other life-threatening and
 debilitating diseases.  Medarex has assembled a broad platform of patented
 technologies for antibody discovery and development, including the UltiMAb(TM)
 Human Antibody Development System(SM) for the creation of high-affinity, fully
 human antibodies; T-12 Development(SM) offering the potential to move from
 target to trial in approximately 12 months; and Trans-Phage Technology(SM)
 combining high throughput screening with fully human antibody development.
 Medarex creates and develops fully human antibodies for itself and others,
 offering a full range of antibody development capabilities, including
 pre-clinical and clinical manufacturing services.  For more information about
 Medarex, visit its Web site at http://www.medarex.com .
 
     Except for the historical information presented herein, matters discussed
 in this press release are forward-looking statements that are subject to
 certain risks and uncertainties that could cause actual results to differ
 materially from any future results, performance or achievements expressed or
 implied by such statements.  Statements that are not historical facts,
 including statements preceded by, followed by, or that include the words
 "believes"; "anticipates"; "plans"; "expects"; "estimates"; or similar
 statements are forward-looking statements.
 
     For Medarex:  Risks and uncertainties include risks associated with
 product discovery and development as well as risks detailed from time to time
 in Medarex's public disclosure filings with the U.S. Securities and Exchange
 Commission (SEC), including its Annual Report on Form 10-K for the fiscal year
 ended December 31, 1999, subsequent Form 10-Q and Form 8-K filings or in
 Genmab's filings with the Copenhagen Stock Exchange and the Neuer Markt.
 Copies of Medarex's public disclosure filings are available from its investor
 relations department.  There can be no assurance that such development efforts
 will succeed, that such products will receive required regulatory clearance or
 that, even if such regulatory clearance were received, such products would
 ultimately achieve commercial success.
 
     HuMAb-Mouse(R) is a registered trademark of Medarex, Inc.  UltiMAb(TM) is
 a trademark of Medarex, Inc.  Human Antibody Development System(SM), T-12
 Development(SM) and Trans-Phage Technology(SM) are service marks of Medarex,
 Inc.
 
 SOURCE  Genmab A/S